
|Articles|June 19, 2019
- Psychiatric Times Vol 36, Issue 6
- Volume 36
- Issue 6
Patient Interviewing 101
Author(s)Richard M. Berlin, MD
Always ask the name of their dog.
Advertisement
Always ask the name of their dog.
Though silence is a tool that works,
the best interviews are dialogues.
Patients reveal more after Buster barks.
Though silence is a tool that works,
you want them engaged when you do your job.
Buster’s presence creates a spark-
their joy animates the dialogue.
You want them engaged when you do your job.
Each session spans an empathic arc
where joy animates the dialogue.
Patients reveal more after Buster barks.
Each session spans an empathic arc.
Let the interview unfold as dialogue
and patients will reveal the way they bark.
Always ask the name of their dog.
Articles in this issue
over 7 years ago
Overcoming Treatment Resistance: Can Pharmacogenetics Help?over 7 years ago
Treating Patients With Comorbid Anxiety and Diabetes Mellitusover 7 years ago
Chatbots: What Are They and Why Care?over 7 years ago
The FDA on ECT: Supporting a Vital Treatmentover 7 years ago
Serial Pleasuresover 7 years ago
Strategies to Facilitate a Positive Clinical Encounterover 7 years ago
Medication-Assisted Treatment on a Budget: Two You Should KnowAdvertisement
Related to this article

Explore the urgent legal, ethical, and clinical challenges in emergency psychiatry, share cases and tips, and contribute to Psychiatric Times’ November series.

Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.

BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.

GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.

Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.

Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Presenting Our November 2026 Theme: Emergency Psychiatry
2
Dementia and the Tuberculosis Vaccine: Reduced Tau Burden With Administration in Mice
3
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
4
GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders
5


